SG11201702103XA - Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment - Google Patents

Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Info

Publication number
SG11201702103XA
SG11201702103XA SG11201702103XA SG11201702103XA SG11201702103XA SG 11201702103X A SG11201702103X A SG 11201702103XA SG 11201702103X A SG11201702103X A SG 11201702103XA SG 11201702103X A SG11201702103X A SG 11201702103XA SG 11201702103X A SG11201702103X A SG 11201702103XA
Authority
SG
Singapore
Prior art keywords
peg
antibodies
cancer treatment
reduced cross
arginine deiminase
Prior art date
Application number
SG11201702103XA
Other languages
English (en)
Inventor
Robert Almassy
James A Thomson
Richard Showalter
Wes Sisson
Wei-Jong Shia
Li-Chang Chen
Yang Lee
Original Assignee
Polaris Group
Richard Showalter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group, Richard Showalter filed Critical Polaris Group
Publication of SG11201702103XA publication Critical patent/SG11201702103XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006Arginine deiminase (3.5.3.6)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201702103XA 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment SG11201702103XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051182P 2014-09-16 2014-09-16
PCT/US2015/050354 WO2016044376A1 (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
SG11201702103XA true SG11201702103XA (en) 2017-04-27

Family

ID=55453727

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702103XA SG11201702103XA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
SG10202002557SA SG10202002557SA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202002557SA SG10202002557SA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Country Status (11)

Country Link
US (1) US9789170B2 (enrdf_load_stackoverflow)
EP (2) EP3193913B1 (enrdf_load_stackoverflow)
JP (2) JP6782230B2 (enrdf_load_stackoverflow)
KR (1) KR102730989B1 (enrdf_load_stackoverflow)
CN (2) CN114522225B (enrdf_load_stackoverflow)
AU (1) AU2015317848B2 (enrdf_load_stackoverflow)
CA (1) CA2961602A1 (enrdf_load_stackoverflow)
ES (1) ES2915382T3 (enrdf_load_stackoverflow)
SG (2) SG11201702103XA (enrdf_load_stackoverflow)
TW (2) TWI775160B (enrdf_load_stackoverflow)
WO (1) WO2016044376A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968482B1 (en) 2013-03-15 2020-05-06 TDW Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
WO2016044376A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
MX2019001770A (es) 2016-08-18 2019-12-05 Meharry Medical College Inhibidores de la invasion intracelular.
EP3519429B1 (en) * 2016-09-29 2021-11-10 Meharry Medical College Peptides derived from s. cristatus arginine deiminase as bacterial inhibitors
EP3534963B1 (en) * 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
CN110461354A (zh) 2017-03-29 2019-11-15 瑞华药业集团 蛋白质缀合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
AU2001275810A1 (en) 2000-07-27 2002-02-13 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
WO2002044360A2 (en) 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
ES2477118T3 (es) 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
CN1536079A (zh) * 2003-04-09 2004-10-13 上海复旦张江生物医药股份有限公司 修饰的精氨酸脱亚氨酶
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20070212311A1 (en) 2003-10-07 2007-09-13 University Of Florida Research Foundation, Inc. Recombinant Alkalinizing Bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20120015049A1 (en) 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
CN101591649B (zh) * 2009-07-10 2013-02-13 江苏泰康生物医药有限公司 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用
US20110111403A1 (en) 2009-10-30 2011-05-12 Life Technologies Corporation Multi-primer assay for mycoplasma detection
CN101812438B (zh) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US20120148559A1 (en) * 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
US9731028B2 (en) * 2012-04-04 2017-08-15 Polaris Group Methods of treatment with arginine deiminase
EP2968482B1 (en) * 2013-03-15 2020-05-06 TDW Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
WO2016044376A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Also Published As

Publication number Publication date
TWI775160B (zh) 2022-08-21
CN107073085A (zh) 2017-08-18
AU2015317848B2 (en) 2021-04-22
WO2016044376A1 (en) 2016-03-24
US20160074487A1 (en) 2016-03-17
EP3193913B1 (en) 2022-05-11
KR20170104986A (ko) 2017-09-18
JP2017529366A (ja) 2017-10-05
EP3193913A1 (en) 2017-07-26
CA2961602A1 (en) 2016-03-24
TW201625295A (zh) 2016-07-16
CN114522225B (zh) 2025-07-25
TW202103730A (zh) 2021-02-01
JP6782230B2 (ja) 2020-11-11
JP2021004268A (ja) 2021-01-14
EP3193913A4 (en) 2018-07-18
JP6961061B2 (ja) 2021-11-05
KR102730989B1 (ko) 2024-11-14
TWI708612B (zh) 2020-11-01
ES2915382T3 (es) 2022-06-22
CN114522225A (zh) 2022-05-24
EP4104853A1 (en) 2022-12-21
US9789170B2 (en) 2017-10-17
SG10202002557SA (en) 2020-04-29
CN107073085B (zh) 2022-02-18
AU2015317848A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
HUS2500001I1 (hu) Antitestkészítmények daganatkezelésre
ZA201605660B (en) Multispecific antibodies
PL3227332T3 (pl) Wielospecyficzne przeciwciała
HUE052526T2 (hu) Antitestek, amelyek tartalmaznak módosított nehéz konstans régiókat
GB201414823D0 (en) Multispecific antibodies
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
SG11201507354QA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
SG11201702103XA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
IL250507B (en) Anti-ck8 antibodies for use in cancer treatment
IL246558A0 (en) New methods of cancer treatment
IL247988A0 (en) Antibodies against hpa–1a
GB201413942D0 (en) Peptides useful for treating cancer